Research Synthesis: Resveratrol Intervention Resveratrol Supplementation Effects

Research Synthesis: Resveratrol Intervention Resveratrol Supplementation Effects

Abstract

Evidence-honesty note: 9/12 retained sources are indirect, review-level, adjacent, or mechanistic and are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.

This synthesis tests the thesis that evidence for Resveratrol Supplementation Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Resveratrol, a polyphenol with purported anti-inflammatory and antioxidant properties, has been extensively investigated for its potential benefits in cardiometabolic and immune-related conditions, yet the clinical evidence remains heterogeneous across populations and dosing regimens.

This synthesis employed an AI-assisted structured evidence synthesis approach with an audit trail to integrate findings from 12 curated reference papers spanning systematic reviews, meta-analyses, and randomized controlled trials to evaluate resveratrol supplementation effects.

These immune outcomes show a more consistent positive signal compared to cardiometabolic endpoints, with agreement across both the meta-analytic and direct RCT evidence (Tabrizi 2018; Keramatzadeh 2025).

The evidence profile indicates that the evidence supports a context-dependent profile for resveratrol supplementation: anti-inflammatory effects appear relatively consistent in metabolic syndrome and autoimmune populations, but cardiometabolic, bone, and pharmacokinetic outcomes remain inconsistent, with null findings predominating in many dosing-relevant endpoints.

The resveratrol anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed human-RCT evidence, and boundary conditions regarding optimal dose, population selection, and clinical endpoints require further establishment through well-designed trials.

Evidence-abstraction note. The 12 retained reference papers are not 12 independent primary clinical trials: 9 are review, indirect, or mechanistic source-level summaries, and 3 are classified as direct interventional evidence. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Methods

Review type and protocol

This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-resveratrol_intervention_resveratrol_supplementation_effects-v06-DAILY-2026-06-08T00-17-14Z-R2.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-08.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• resveratrol intervention resveratrol supplementation effects aging
• resveratrol intervention resveratrol supplementation effects older adults
• resveratrol intervention resveratrol supplementation effects randomized controlled trial
• resveratrol aging
• resveratrol older adults
• resveratrol randomized controlled trial
• intervention resveratrol supplementation aging
• intervention resveratrol supplementation older adults
• intervention resveratrol supplementation randomized controlled trial

Eligibility criteria

• Sources whose primary content addresses resveratrol intervention resveratrol supplementation effects.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 183 records in the receipt-candidate union, 63 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	183
Classified source candidates	63
No extractable claims	1
None-only claim binding	0
Mixed partial-or-none claim-binding candidates	9
Partial-only claim-binding candidates	7
Strict high-confidence sources	7
Admitted final sources	12

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, dosing and pharmacokinetics, immune); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

The retained resveratrol intervention resveratrol supplementation effects corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints.

Dosing and Pharmacokinetics Outcomes

The dosing and pharmacokinetics evidence packet includes 8 source-level summaries and 584 high-confidence observations. Directional coding within this packet is negative=1, null=4, positive=1, unclear=2, and directness coding is direct=1, indirect=2, review=5. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Representative sources: Li 2021, SHEN 2026, Wong 2020.

Cardiometabolic Outcomes

The cardiometabolic evidence packet includes 2 source-level summaries and 49 high-confidence observations. Directional coding within this packet is positive=1, unclear=1, and directness coding is direct=1, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Representative sources: Nyambuya 2020, Faghihzadeh 2015.

Immune Outcomes

The immune evidence packet includes 2 source-level summaries and 6 high-confidence observations. Directional coding within this packet is positive=2, and directness coding is direct=1, review=1. These counts describe the frozen evidence state for this outcome, not a pooled treatment estimate.

Representative sources: Tabrizi 2018, Keramatzadeh 2025.

Across outcome classes, the manuscript treats disagreement as part of the evidence rather than as noise to smooth away. A null or adverse signal in one section does not cancel a favorable signal in another; it defines the boundary condition for interpretation.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

Notably absent are large-scale, long-term randomized controlled trials (RCTs) designed to assess the impact of resveratrol supplementation on all-cause mortality or major adverse cardiac events (MACE) in a general adult population. This gap means that while the synthesis can evaluate effects on inflammatory markers or glycemic control, it cannot draw conclusions about resveratrol's efficacy in preventing the ultimate clinical endpoints of aging and chronic disease. The evidence base for anti-aging claims, therefore, remains mechanistic and incomplete, relying on intermediate measures whose clinical validity is an area of active investigation (Ioannidis 2005).

Several key outcome domains are represented by only a single study within this corpus, precluding any internal replication of findings. For instance, the positive effect on immune markers like TNF-α in multiple sclerosis patients is reported solely by Keramatzadeh 2025. The evidence for effects on sympathetic nervous system activity and vascular reactivity is based on the work of Goncalinho 2021 alone. Conclusions drawn from these single-trial domains are inherently fragile and susceptible to the idiosyncrasies of small, specific study populations.

The external validity of the synthesized findings is constrained by the specific populations enrolled in the constituent trials. Other trials enrolled overweight or slightly obese adults (Made 2017, Goncalinho 2021) or specific patient groups like those with chronic periodontitis (Nikniaz 2023) or non-alcoholic fatty liver disease (Faghihzadeh 2015). Consequently, the applicability of these results to healthy, non-diabetic adults, older adults experiencing age-related frailty, or other demographic groups cannot be confidently assumed from the available corpus.

The synthesis reveals significant heterogeneity and unresolved tension within the evidence for resveratrol's effects on dosing and pharmacokinetic outcomes. Positive signals from meta-analyses in diabetic cohorts (Zhu 2025, Nyambuya 2020) directly contrast with null findings from individual trials in similar or different populations (Li 2021, Nikniaz 2023, Sangouni 2022). Furthermore, one review reports a negative effect direction (SHEN 2026). This disagreement, evidenced by multiple meta-analyses reaching opposing conclusions, suggests that the true effect is highly context-dependent or that the current literature is insufficiently mature to resolve the question. The mechanism by which resveratrol might exert a benefit on bone mineral density remains unclear, as the large RESHAW trial reported an effect direction that was not definitively positive (Wong 2020).

Conclusion

For resveratrol supplementation effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support resveratrol supplementation effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 12 included sources on Resveratrol Supplementation Effects across 3 outcome classes and 25 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 12 curated reference papers, the evidence base for Resveratrol Supplementation Effects shows a context-dependent profile. Positive signals appear in: immune, dosing pharmacokinetics. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Resveratrol Intervention Resveratrol Supplementation Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the disagreement between Zhu 2025 and SHEN 2026 on dosing and pharmacokinetics (severity 5/5), which defines the boundary condition future studies must test rather than smooth over.

Prior reviews in the corpus (Zhu 2025, Nyambuya 2020, Tabrizi 2018) emphasize convergent signals on Resveratrol Supplementation Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Evidence domain	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
cardiometabolic	1	1	positive, unclear	replication gap
immune	1	1	positive	replication gap
dosing and pharmacokinetics	1	7	negative, null, positive, unclear	conflict-resolution gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	cardiometabolic: replication gap	1 direct and 1 indirect sources; direction profile: positive, unclear
P2	immune: replication gap	1 direct and 1 indirect sources; direction profile: positive
P3	dosing and pharmacokinetics: conflict-resolution gap	1 direct and 7 indirect sources; direction profile: negative, null, positive, unclear

Next-Study Design Recommendation

The next high-yield study for Resveratrol Supplementation Effects should target the cardiometabolic evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 100 participants per arm, a priority population of the same population type as the strongest direct source cluster, and follow-up lasting at least 24 weeks; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Made 2017; tier=A1; directness=direct; endpoint=dosing pharmacokinetics; direction=unclear; representative statistic=P < 0.001.
• Keramatzadeh 2025; tier=A1; directness=direct; endpoint=immune; direction=positive; representative statistic=P < 0.001.
• Faghihzadeh 2015; tier=A1; directness=direct; endpoint=cardiometabolic; direction=unclear.
• Zhu 2025; tier=B1; directness=review; endpoint=dosing pharmacokinetics; direction=positive; representative statistic=P < 0.00001.
• Nyambuya 2020; tier=B1; directness=review; endpoint=cardiometabolic; direction=positive; representative statistic=P = 0.001.
• Tabrizi 2018; tier=B1; directness=review; endpoint=immune; direction=positive; representative statistic=P < 0.001.
• Li 2021; tier=B2; directness=review; endpoint=dosing pharmacokinetics; direction=null; representative statistic=P = 0.26.
• SHEN 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=negative; representative statistic=P = 0.066.
• Wong 2020; tier=B2; directness=review; endpoint=dosing pharmacokinetics; direction=unclear.
• Nikniaz 2023; tier=B2; directness=review; endpoint=dosing pharmacokinetics; direction=null.

Source Classification Map

Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.

• Trans -Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants: outcome=dosing pharmacokinetics; directness=direct; tier=A1; direction=unclear; claims=76.
• Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.: outcome=immune; directness=direct; tier=A1; direction=positive; claims=2.
• The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.: outcome=cardiometabolic; directness=direct; tier=A1; direction=unclear; claims=1.
• The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis: outcome=dosing pharmacokinetics; directness=review; tier=B1; direction=positive; claims=53.
• A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy: outcome=cardiometabolic; directness=review; tier=B1; direction=positive; claims=48.
• The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials.: outcome=immune; directness=review; tier=B1; direction=positive; claims=4.
• Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=151.
• Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=negative; claims=89.
• Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=unclear; claims=82.
• Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trial: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=65.
• Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=null; claims=36.
• Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial: outcome=dosing pharmacokinetics; directness=review; tier=B2; direction=null; claims=32.

Classification Criteria

• Outcome class is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.
• Directness is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.
• Directional signal is counted within the assigned outcome class only. A no extracted directional signal cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.
• Evidence tier follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.

Load-Bearing Tensions

• Severity 5 disagreement: Zhu 2025 vs SHEN 2026; Zhu 2025 (positive) vs SHEN 2026 (negative) on dosing pharmacokinetics
• Severity 3 null vs positive: Nikniaz 2023 vs Zhu 2025; Nikniaz 2023 (null) vs Zhu 2025 (positive) on dosing pharmacokinetics
• Severity 3 null vs positive: Nikniaz 2023 vs SHEN 2026; Nikniaz 2023 (null) vs SHEN 2026 (negative) on dosing pharmacokinetics
• Severity 3 null vs positive: Nikniaz 2023 vs Made 2017; Nikniaz 2023 (null) vs Made 2017 (unclear) on dosing pharmacokinetics
• Severity 3 null vs positive: Nikniaz 2023 vs Wong 2020; Nikniaz 2023 (null) vs Wong 2020 (unclear) on dosing pharmacokinetics
• Severity 3 null vs positive: Zhu 2025 vs Goncalinho 2021; Zhu 2025 (positive) vs Goncalinho 2021 (null) on dosing pharmacokinetics
• Severity 3 null vs positive: Zhu 2025 vs Li 2021; Zhu 2025 (positive) vs Li 2021 (null) on dosing pharmacokinetics
• Severity 3 null vs positive: Zhu 2025 vs Sangouni 2022; Zhu 2025 (positive) vs Sangouni 2022 (null) on dosing pharmacokinetics

References

• Li 2021. Effects of resveratrol supplementation on bone quality: a systematic review and meta-analysis of randomized controlled trials. BMC Complementary Medicine and Therapies, 2021. DOI: 10.1186/s12906-021-03381-4. PMID: 34420523.
• SHEN 2026. Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases. In Vivo, 2026. DOI: 10.21873/invivo.14235. PMID: 41760304.
• Wong 2020. Regular Supplementation With Resveratrol Improves Bone Mineral Density in Postmenopausal Women: A Randomized, Placebo‐Controlled Trial. Journal of Bone and Mineral Research, 2020. DOI: 10.1002/jbmr.4115. PMID: 32564438.
• Made 2017. Trans -Resveratrol Supplementation and Endothelial Function during the Fasting and Postprandial Phase: A Randomized Placebo-Controlled Trial in Overweight and Slightly Obese Participants. Nutrients, 2017. DOI: 10.3390/nu9060596. PMID: 28604618.
• Nikniaz 2023. Impact of resveratrol supplementation on clinical parameters and inflammatory markers in patients with chronic periodontitis: a randomized clinical trail. BMC Oral Health, 2023. DOI: 10.1186/s12903-023-02877-4. PMID: 36973728.
• Zhu 2025. The efficacy of resveratrol supplementation on inflammation and oxidative stress in type-2 diabetes mellitus patients: randomized double-blind placebo meta-analysis. Frontiers in Endocrinology, 2025. DOI: 10.3389/fendo.2024.1463027. PMID: 39872318.
• Nyambuya 2020. A Meta-Analysis of the Impact of Resveratrol Supplementation on Markers of Renal Function and Blood Pressure in Type 2 Diabetic Patients on Hypoglycemic Therapy. Molecules, 2020. DOI: 10.3390/molecules25235645. PMID: 33266114.
• Goncalinho 2021. Comparison of Resveratrol Supplementation and Energy Restriction Effects on Sympathetic Nervous System Activity and Vascular Reactivity: A Randomized Clinical Trial. Molecules, 2021. DOI: 10.3390/molecules26113168. PMID: 34073163.
• Sangouni 2022. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovascular Disorders, 2022. DOI: 10.1186/s12872-022-02637-2. PMID: 35538431.
• Tabrizi 2018. The effects of resveratrol supplementation on biomarkers of inflammation and oxidative stress among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Food Funct, 2018. DOI: 10.1039/c8fo01259h. PMID: 30426122.
• Keramatzadeh 2025. Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial. Nutr Neurosci, 2025. DOI: 10.1080/1028415x.2024.2425649. PMID: 39565038.
• Faghihzadeh 2015. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr, 2015. DOI: 10.1017/s0007114515002433. PMID: 26234526.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.